Affibody AB – growing organically with strategic dealmaking

December 14, 2015 Guest Contributor

David Bejker

Guest post by David Bejker, CEO of Affibody


We are a small player on the international life science scene—but with strategic partnerships and alliances with big and medium-sized pharma—we are moving forward rapidly. In fact, last time you visited your protein lab facilities, you might have seen Affibody® molecules in action.

Affibody was founded in 1998 as a spin out from the Royal Institute of Technology, KTH, and the Karolinska Institutet, KI, in Stockholm. Our key proprietary platform is built around the Affibody® molecule—a small, modular and high-affinity protein. You may already have used the properties of an Affibody® molecule if you’ve ever been working with protein purification, as they are the affinity molecule used in GE Healthcare’s MabSelect SuRe columns. Or, you might have enjoyed the unique thermostable properties of the Affibody molecule to enhance your qPCR using Thermo Fischer’s Phusion Hot Start kit.


In a way, the deal that we closed with GE Healthcare in 2004 for the protein purification illustrates how we still do business—in partnerships and strategic alliances with large companies.


And the strategy has proved fruitful. Though designable affinity is still our most valuable asset, today we are developing it for therapeutic applications and are currently evaluating the safety profile in clinical trials. We believe in medicines that are precise and tailored to the indication addressed and have already proven clinical efficacy in changing the way patients have been treated with our imaging agent for women with breast cancer. With seven key therapeutic collaboration agreements in place focusing on various indications and administrative routes, and with several clinical trials under way, Affibody® molecules are very much proving their versatility and usefulness towards treatment of severe disorders.


Our overall business development theme is teaming up and doing business with other companies, to keep a dynamic relation with academia and to catalyze development of great protein therapeutics.


Meet Bejker and executives from other exciting Swedish-based companies at BIO-Europe Spring® in Stockholm Sweden April 4–6, 2016.

Previous Article
Why does your company need a press release to announce participation in an upcoming event?
Why does your company need a press release to announce participation in an upcoming event?

In a digital world, do press releases still have relevance? Before social media took over as the top source...

Next Article
AstraZeneca hones its focus
AstraZeneca hones its focus

AstraZeneca, known as a global leader in innovative collaborations, is honing its focus to three priority a...